cholesterol

Merck & Co. announced encouraging results from its late‑stage trial of an experimental pill that blocks the PCSK9 protein, a breakthrough that could usher in an era of dramatically lower cholesterol levels for millions of patients. Unlike existing PCSK9‑targeting drugs, which must be injected and carry hefty price tags, Merck’s...